Evidence map›Paper›PMID 40835471›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Investigation of Appropriate Telemedicine for Patients with Inflammatory Bowel Disease.

Masaro Nagamatsu, Kayoko Matsushima, Junya Shiota, Taro Akashi, Maiko Tabuchi, Moto Kitayama, Keiichi Hashiguchi, Naoyuki Yamaguchi, Yuko Akazawa, Hisamitsu Miyaaki and 2 more

Abstract read
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Masaro NagamatsuDepartment of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Kayoko MatsushimaDepartment of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Junya ShiotaDepartment of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Taro AkashiDepartment of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Maiko TabuchiDepartment of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Moto KitayamaDepartment of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Keiichi HashiguchiDepartment of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Naoyuki YamaguchiDepartment of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Yuko AkazawaDepartment of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Hisamitsu MiyaakiDepartment of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Fuminao TakeshimaDepartment of General Medicine, Goto Chuo Hospital, Japan.
Kazuhiko NakaoSasebo City General Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective This study explored the conditions for applying telemedicine to patients with inflammatory bowel disease (IBD), attempting to demonstrate that the application of telemedicine to patients with IBD does not adversely affect their condition and clarifying the form of telemedicine that meets the needs of patients with IBD. Methods Study 1 retrospectively investigated the application of telemedicine and its impact on IBD treatment, whereas Study 2 investigated the perceptions of telemedicine in patients with IBD. Patients Study 1 was conducted using the medical records of 267 patients with IBD who had been treated at our department throughout the financial years (FY) 2019 and 2020. In Study 2, a questionnaire survey was presented to 113 patients from Study 1, who agreed to complete the questionnaire. Results No patient background factors significantly influenced telemedicine implementation in FY 2020. A shorter disease duration, relapse in the previous FY, and lower Hb levels were significantly related to relapse in FY 2020, whereas the use of telemedicine was not related to relapse. The survey revealed that most patients with IBD preferred a conventional face-to-face treatment system; however, patients who had difficulty finding the time to visit the hospital tended to prefer telemedicine. Conclusion Telemedicine can be implemented in patients with IBD without adverse effects on their medical conditions; however, the appropriate conditions for applying telemedicine need to be clarified in the future. It is necessary to establish an IBD treatment system that satisfies patients' needs, considering the characteristics of those who wish to receive telemedicine.

Indexed as

Inflammatory Bowel DiseasesTelemedicineAdultAgedFemaleHumansMaleMiddle AgedRecurrenceRetrospective StudiesSurveys and QuestionnairesYoung Adultface-to-face treatmentinflammatory bowel diseaserelapsetelemedicinetreatment

Identifiers

PMID40835471
PMCPMC13106823

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.